Here’s what biotech CFOs learned by going public in a virtual world
INSIGHT ARTICLE |
Like any industry in 2020, the life sciences space has had to adapt to new parameters for remote work amid other pandemic-based constraints, even for critical lab research. The process of taking a company public has been no exception; crucial in-person interactions between investors and executives were forced to go virtual, which led to accelerated timelines for some IPOs.
This fall, in conjunction with CBI Informa Connect’s Finance & Accounting for Bioscience Companies virtual conference, RSM and Pharmaceutical Executive brought together a group of biotechnology CFOs who had recently navigated the IPO process with their organizations. CFOs from Adaptive Biotechnologies, ALX Oncology Holdings, Berkeley Lights, ORIC Pharmaceuticals and Zentalis Pharmaceuticals had a virtual conversation about going public in this COVID-19 environment (only Adaptive went public before the pandemic began).
Read this Pharmaceutical Executive article for insight into what these CFOs learned going through a virtual IPO, including considerations around key hiring decisions, roadshow planning and the process of getting vetted by an outside accounting firm.
Missed the webcast on IPO readiness and transitioning to the public market? Check out this recorded webcast.
Preparation in the IPO process can’t be underestimated. RSM’s experienced team can assist with the process in a timely and effective manner.
This guide will help your stakeholders determine if an IPO is the right path for your company by addressing some basic questions.